Table 1.
Descriptive Data of Meropenem Compliance Indicators, 2022–2023.
Table 2.
Difference in patients’ outcomes between years 2022 and 2023.
Table 3.
Cochran-Armitage Trend test for “Clinical Improvement within 72 hours” outcome across the quarters of years 2022 and 2023.
Table 4.
Cochran-Armitage Trend test for “Transfer/Discharge” outcome across the quarters of years 2022 and 2023.
Table 5.
Comparison of Overall Compliance by Clinical Improvement and Transfer/Discharge Outcomes (2022-2023).
Table 6.
Quarterly Trends in DDD per 1000 Patient-Days and Statistical Comparisons for 2022–2023.
Fig 1.
Meropenem Consumption Across Quarters of 2022-2023: Defined Daily Dose (Blue Bars) and Antimicrobial Cost per Patient Day (Red Line).
Fig 2.
Pattern of meropenem prescription expressed as DDD per 1000 across medical specialties: 2022-2023.
Table 7.
Estimated Cost Savings and Expenditures During the Gradual Implementation of an AMS Program Across Quarters in 2022–2023.